Masonic Cancer Center, University of Minnesota
Members of this program work to improve detection, treatment, and prevention of women's cancers in order to improve outcomes. Toward that end, they seek to discover improved methods for early detection, understand the biology of breast and gynecologic cancers, and enhance treatment through more precisely targeted therapies.
Lange named co-leader of Women's Cancer Research Program
Carol Lange, Ph.D., has been named co-leader of the Masonic Cancer Center's Women's Cancer Research Program. She succeeds cancer center director Douglas Yee, M.D., in this new role and shares leadership responsibilities for the program with Levi Downs, M.D. Lange also was recently promoted to professor and named the Tickle Family Land Grant Endowed Chair in Breast Cancer Research. Her laboratory research focuses on signal transduction in breast cancer, including the study of cross-talk between peptide growth factors and steroid hormone receptors in human breast cancer cells.
Lange speaks at Legislature's Cancer Caucus
Carol Lange, Ph.D., Women's Cancer Research Program, discussed her breast cancer laboratory research at the Minnesota Legislature's Cancer Caucus October 7 at the Capitol. Lange described research that could lead to a better understanding of how breast cancer spreads and have implications for future prevention and treatment. The mission of the cancer caucus is to increase knowledge among legislators about cancer and related health issues and to connect legislators and their constituents to resources related to cancer prevention, treatment and support.
October is Breast Cancer Awareness Month: News, Events, Resources
Putting ovarian cancer into remission (Minnesota Medical Foundation)
An altruistic attitude: Health-care professionals and patients partner up to advance medical knowledge through clinical research (Minnesota Medical Foundation)
Researchers awarded grants from the Minnesota Ovarian Cancer Alliance
Health Talk & You: Another Weapon to Fight Ovarian Cancer
U of M study finds thalidomide shows promise for treatment of recurrent ovarian cancer